309 related articles for article (PubMed ID: 15765377)
1. Radioimmunodetection and therapy of breast cancer.
DeNardo SJ
Semin Nucl Med; 2005 Apr; 35(2):143-51. PubMed ID: 15765377
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach.
Stipsanelli E; Valsamaki P
Hell J Nucl Med; 2005; 8(2):103-8. PubMed ID: 16142251
[TBL] [Abstract][Full Text] [Related]
3. The promise of immuno-PET in radioimmunotherapy.
Verel I; Visser GW; van Dongen GA
J Nucl Med; 2005 Jan; 46 Suppl 1():164S-71S. PubMed ID: 15653665
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
Sharkey RM; Goldenberg DM
J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660
[TBL] [Abstract][Full Text] [Related]
5. Antibody-based cancer therapies: back to "polyclonals"?
Paganelli G; De Santis R
Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1453-5. PubMed ID: 15258701
[No Abstract] [Full Text] [Related]
6. The promise of targeted {alpha}-particle therapy.
Mulford DA; Scheinberg DA; Jurcic JG
J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670
[TBL] [Abstract][Full Text] [Related]
7. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu H; Jain RK; Baxter LT
J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
[TBL] [Abstract][Full Text] [Related]
8. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
[TBL] [Abstract][Full Text] [Related]
9. Antibody-based targeted radiation to pediatric tumors.
Modak S; Cheung NK
J Nucl Med; 2005 Jan; 46 Suppl 1():157S-63S. PubMed ID: 15653664
[TBL] [Abstract][Full Text] [Related]
10. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
11. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
12. Cure of incurable lymphoma.
DeNardo GL; Sysko VV; DeNardo SJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S46-56. PubMed ID: 16979440
[TBL] [Abstract][Full Text] [Related]
13. Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies.
Richman CM; DeNardo SJ
Crit Rev Oncol Hematol; 2001 Apr; 38(1):25-35. PubMed ID: 11255079
[TBL] [Abstract][Full Text] [Related]
14. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
15. Current status of therapy of solid tumors.
Jhanwar YS; Divgi C
J Nucl Med; 2005 Jan; 46 Suppl 1():141S-50S. PubMed ID: 15653662
[TBL] [Abstract][Full Text] [Related]
16. Current status of therapy of solid tumors: brain tumor therapy.
Zalutsky MR
J Nucl Med; 2005 Jan; 46 Suppl 1():151S-6S. PubMed ID: 15653663
[TBL] [Abstract][Full Text] [Related]
17. [Radiolabeled antibodies for cancer treatment].
Barbet J; Chatal JF; Kraeber-Bodéré F
Med Sci (Paris); 2009 Dec; 25(12):1039-45. PubMed ID: 20035676
[TBL] [Abstract][Full Text] [Related]
18. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
[TBL] [Abstract][Full Text] [Related]
19. New insights into the pretargeting approach to image and treat tumours.
Patra M; Zarschler K; Pietzsch HJ; Stephan H; Gasser G
Chem Soc Rev; 2016 Nov; 45(23):6415-6431. PubMed ID: 27722526
[TBL] [Abstract][Full Text] [Related]
20. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
